AbbVie publicly refuted Wall Street Journal reports that it was in advanced negotiations to acquire cancer-drug developer Revolution Medicines. The denial came after Revolution shares surged as much as 29% intraday, only to plunge 11.5% in after-hours trading once AbbVie confirmed to Reuters that no discussions were underway. AbbVie’s statement underscores its disciplined approach to capital allocation and suggests the company remains focused on organic growth in oncology rather than sizeable biotech buyouts at this time.

AbbVie announced it will release its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. The company will host a live webcast of its earnings conference call at 8:00 a.m. Central time, accessible via its Investor Relations website. An archived recording will be made available later that day. Investors will be keen to hear updates on AbbVie’s performance in its key therapeutic areas—immunology, oncology, neuroscience and eye care—as well as progress in integrating its Allergan Aesthetics portfolio and managing its debt levels following recent pipeline investments.